by Simona Gilman | Jun 25, 2020 | Featured Posts, Press Releases
A transformative innovation GeminiTM, the in silico patient, will drive better drug development, clinical trial design and generation of real-world evidence in multiple myeloma GNS Healthcare, an AI-driven precision medicine company, today announced the launch of...
by Simona Gilman | Jun 18, 2020 | Press Releases
Partnership Aims to Answer Key Questions in Multiple Myeloma Patient Care and Accelerate Discovery and Development of New Treatments Cambridge, MA – June 18, 2020– GNS Healthcare and the Multiple Myeloma Research Foundation (MMRF) today announced a five-year...
by Simona Gilman | Jun 9, 2020 | Webinar
Despite the unprecedented success of immune checkpoint inhibitors (ICI) in several cancer types, only a subset of patients derives clinical benefit. Companies leading the charge on ICI development are faced with many questions including: What are the molecular drivers...
by Simona Gilman | May 28, 2020 | Press Releases
Study results are from the DREAM Challenge and are published in Leukemia CAMBRIDGE, Mass.– May 28, 2020 – GNS Healthcare (GNS), a leading AI-driven precision medicine, announced results of a recently published collaboration that uncovered transcription factor PHF19 as...
by Simona Gilman | Apr 21, 2020 | Press Releases
Michael Bonney, Tom Daniel, Peter Neupert, and Lee Newcomer join GNS Healthcare’s in silico Patient Advisory Board Cambridge, MA – April 21, 2020 – GNS Healthcare, an AI-driven precision medicine company, is pleased to announce the formation of its in silico Patient...
